One green flag, for example, is if the company is reporting growth in its genomics business, which provides next-generation sequencing (NGS). In 2022 and 2023, Tempus AI reported year-over-year ...

Tempus AI should remain a long-term beneficiary of next-generation sequencing, which is at a tipping point as it rapidly becomes the standard of care, Loop added. See what stocks are receiving ...

an FDA-approved 648-gene Next Generation Sequencing test, provides clinicians with a powerful, regulatory-cleared diagnostic tool for solid tumors, further solidifying Tempus AI's position in the ...

Ordering physicians were not required to order both sequencing and PD-L1 immunohistochemistry (IHC). Tempus xT next-generation sequencing assay results were analyzed as previously described. 18 ...

Next-generation DNA sequencing has started a revolution in genomics and created the opportunity for large-scale sequencing projects, such as the recently announced 1,000 Genomes Project—an ...

Next-generation sequencing (NGS) of both tissue and ctDNA ... Tissue samples were analysed using the Tempus xT tumour normal assay, an NGS-based cancer genome profiling test that interrogates ...

Skyrocketing 108% since the start of 2025, Tempus AI (NASDAQ: TEM), a company applying AI solutions to healthcare, has seen its stock perform exceptionally well this year. Investors have found the ...